Healthline

Side Effects of Copaxone: What You Need to Know

Copaxone is a prescription drug used to treat different types of multiple sclerosis (MS) in adults. It can cause side effects that range from mild to serious, including injection site reactions, ...
Medscape

FDA Approves 3-Times-a-Week Copaxone in MS

The US Food and Drug Administration (FDA) has approved a higher-dose, lower-frequency regimen for glatiramer acetate (Copaxone, Teva Pharmaceutical Industries) in the treatment of relapsing-remitting ...
FierceBiotech

Teva Presents New Data Which Demonstrate Reduction of Injection-Related Adverse Events with the Less Frequent Dosing of Three-times-a-week COPAXONE® (glatiramer acetate ...

<0> Teva Pharmaceutical Industries Ltd.IR:United States 215-591-8912or215-591-3033orIsrael 972 (3) 926-7656orPR:Israel 972 (3) 926-7687orUnited States 215-591-8974or215-284-0213 </0> Teva ...
FiercePharma

TEVA ANNOUNCES COPAXONE® REACHES ONE MILLION PATIENT YEARS OF EXPERIENCE IN THE TREATMENT OF MULTIPLE SCLEROSIS

Approved in 1996, Copaxone® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
FiercePharma

Teva Announces Approval of COPAXONE® in Japan for the Prevention of Relapse of Multiple Sclerosis

JERUSALEM--(BUSINESS WIRE)--Sep. 28, 2015-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) announced today the approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) of ...
Business Wire

Zydus Receives Final Approval From USFDA for Glatiramer Acetate Injection, the Generic Version of Copaxone® 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes

AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...